Technology-Enhanced Therapy vs. Medication Monitoring for Buprenorphine Retention in Pregnant Persons

Date Added
December 3rd, 2024
PRO Number
Pro00141060
Researcher
Sara Witcraft

List of Studies

Keywords
Anxiety, Mental Health, Pregnancy, Psychiatry, Sleep Disorders, Substance Use, Women's Health
Summary

This study involves testing how useful a technology-enhanced, skill building intervention is for pregnant people prescribed buprenorphine for the treatment of opioid use disorder, compared to medication monitoring. Participants are randomized to one of the conditions. Participants randomized to receive the skill building intervention will attend three 60-90-minute therapy appointments during pregnancy with an additional 30-minute therapy session towards the end of pregnancy, and 3 additional monthly postpartum (after childbirth) sessions (0-6 months postpartum). As part of the program, participants will receive access to a mobile application, which will be accessible for the duration of the study. Participants randomized to medication monitoring will be asked to log each time the medication is taken for a two month period. All participants will also be asked to complete questionnaires at enrollment, at the end of pregnancy, 3-month postpartum, and 6-months postpartum, be contacted randomly throughout the study to perform a medication count, and complete a urine drug screen at 6-months postpartum. The total duration of the study is between 9-13 months depending on when enrollment occurs (early second trimester-mid third trimester). Compensation up to $500 is provided.

Institution
MUSC
Recruitment Contact
Maham Dilawar
843-214-4496
dilawarm@musc.edu

Modified cardiac rehabilitation to enhance post-stroke physical and psychosocial function: does depression limit the response?

Date Added
December 3rd, 2024
PRO Number
Pro00140518
Researcher
Ryan Ross

List of Studies

Keywords
Depression, Exercise, Stroke, Stroke Recovery
Summary

Cardiac rehabilitation is the standard-of-care treatment option for patients with cardiovascular disease and has been shown to improve many aspects critical to patient recovery. We believe that individuals who have had a stroke need to be treated similarly. We will study the effects of a comprehensive modified cardiac rehabilitation program to determine if it can improve some of the physical and psychosocial problems common in survivors of stroke with and without depression.

Institution
MUSC
Recruitment Contact
Ryan Ross
843-792-3477
rossre@musc.edu

SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistula Study

Date Added
December 3rd, 2024
PRO Number
Pro00140475
Researcher
Cary Brewton

List of Studies

Keywords
Kidney
Summary

This multi-center, prospective, randomized, clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of the SelfWrap, a bioabsorbable perivascular wrap, for supporting surgically-created AVFs and using them for dialysis.

This study will involve approximately 200 participants. Half of the subjects in this trial will receive AVFs supported by the SelfWrap, while the other half will receive a traditional AVF alone. Participants will be followed for a duration of 36 months.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Patricia Robinson
843-674-5175
robinpat@musc.edu

Portable Transcranial Magnetic Stimulation (TMS) in a Van for Treatment-Resistant Depression

Date Added
December 3rd, 2024
PRO Number
Pro00139739
Researcher
Mark George

List of Studies


Keywords
Anxiety, Depression
Summary

In this pilot study we will assemble a portable TMS(transcranial magnetic stimulation) unit, in a van, and then test out delivering TMS in Medical University of South Carolina (MUSC)-affiliated facilities in South Carolina, all within 90 minutes of driving from Charleston, SC. This work will hopefully open up access to TMS for millions of patients with treatment-resistant depression who cannot be treated in the current model.
We will recruit up to 30 treatment-resistant depression patients who live near one of the MUSC-affiliated clinics. We will treat these patients, open-label, with FDA-approved accelerated TMS (6 sessions each day, over 2 hours, for 5 days, spread over one or two weeks). We will measure TMS effectiveness using standard depression rating scales.

Institution
MUSC
Recruitment Contact
Alexandra Herron
843 876 9004
herronal@musc.edu

Portable Transcranial Magnetic Stimulation (TMS) in a Van for Treatment-Resistant Depression

Date Added
December 3rd, 2024
PRO Number
Pro00139739
Researcher
Mark George

List of Studies


Keywords
Anxiety, Depression
Summary

In this pilot study we will assemble a portable TMS(transcranial magnetic stimulation) unit, in a van, and then test out delivering TMS in Medical University of South Carolina (MUSC)-affiliated facilities in South Carolina, all within 90 minutes of driving from Charleston, SC. This work will hopefully open up access to TMS for millions of patients with treatment-resistant depression who cannot be treated in the current model.
We will recruit up to 30 treatment-resistant depression patients who live near one of the MUSC-affiliated clinics. We will treat these patients, open-label, with FDA-approved accelerated TMS (6 sessions each day, over 2 hours, for 5 days, spread over one or two weeks). We will measure TMS effectiveness using standard depression rating scales.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Alexandra Herron
843 876 9004
herronal@musc.edu

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Post-Operative Steroids after Sleep Surgery

Date Added
December 3rd, 2024
PRO Number
Pro00138969
Researcher
Mohamed Abdelwahab

List of Studies

Keywords
Pain, Sleep Disorders, Surgery
Summary

The purpose of this study is to study the effectiveness of steroids after sleep surgery in improving pain, reducing difficulties in swallowing, and reducing the amount of narcotic pain medication after surgery. This study also want to see what dosage of steroids, whether intravenous or oral, are more effective at reducing these symptoms and providing a more effective surgical procedure for your sleep apnea. Anyone planning to undergo sleep surgery for your obstructive sleep apnea at the recommendation of the Sleep Surgery Division here at MUSC is invited to participate in this study. The study will be using both intravenous and oral dexamethasone, a very common and widely used steroid. This steroid has been FDA approved for many medical indications.

Institution
MUSC
Recruitment Contact
Nicolas Poupore
843-792-8299
poupore@musc.edu

A first-in-human, non-significant risk study of the ViewFlex X ICE system

Date Added
November 26th, 2024
PRO Number
Pro00140797
Researcher
Jeffrey Winterfield

List of Studies


Keywords
Heart
Summary

This study involves collecting data and physician feedback while using the ViewFlex X System during a routine electrophysiology (EP) procedure. An electrophysiology procedure is done to correct an electrical abnormality in the heart. The ViewFlex X System is considered investigational meaning it has not been approved for commercial use by the Food and Drug Administration (FDA). The ViewFlex System will obtain and integrate heart images with the mapping information obtained during your procedure. There is also an option to have the procedure videotaped. Study participation lasts until hospital discharge post procedure. Study related risks include risks associated with using the ViewFlex X System, loss of confidentiality and unknown risks.

Institution
MUSC
Recruitment Contact
Deborah Everidge
843-792-2944
adamsde@musc.edu

Morbidity of locally recurrent cutaneous squamous cell carcinoma – a comparative case-control study

Date Added
November 25th, 2024
PRO Number
Pro00140037
Researcher
Joel Cook

List of Studies


Keywords
Cancer/Skin
Summary

To determine if locally recurrent cutaneous squamous cell carcinoma (cSCC) leads to increased patient morbidity, and, if so, to what extent. The main outcome will be the margin required to clear locally recurrent cSCC versus that of similar primary cSCC. Secondary outcomes will analyze number of mohs micrographic surgery (MMS) layers, the difference in area between the clinical lesion and the defect size, closure types and sizes, loss of function, and referrals (radiation, oncology, reconstruction, etc.) required for treatment.

Institution
MUSC
Recruitment Contact
Siddharth Srikakolapu
8438765074
srikakol@musc.edu

A Non-randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

Date Added
November 22nd, 2024
PRO Number
Pro00140162
Researcher
Maggie Westfal

List of Studies

Keywords
Cancer, Cancer/Gynecological, Women's Health
Summary

BRCA1 mutations are errors in genes that can be inherited and may predispose you to ovarian cancer. This study is for women who have a BRCA1 mutation and have elected to undergo a surgical intervention. Surgical intervention is to compare the non-inferiority of bilateral salpingectomy (BLS) with delayed oophorectomy to bilateral salpingo-oophorectomy (BSO) to reduce the risk of ovarian cancer among individuals with deleterious BRCA1 germline mutations.

Institution
MUSC
Recruitment Contact
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu

ABSORBABLE ANTIBACTERIAL SOFT TISSUE SUPPORT IN BREAST RECONSTRUCTION WITH INFECTION OUTCOMES ASSESSMENT

Date Added
November 22nd, 2024
PRO Number
Pro00139591
Researcher
Gabriel Klein

List of Studies

Keywords
Surgery
Summary

This study is being conducted in women who are at least 22 years old,+ and will be undergoing either a unilateral or bilateral mastectomy with immediate two-stage post-mastectomy alloplastic prepectoral breast reconstruction (initial insertion of a tissue expander on top of the chest wall muscle followed by change-over to a breast implant after a period of tissue expander inflation).

The purpose of this research study is to evaluate the safety and effectiveness of the Melodi Matrix. .

The Melodi Matrix is an absorbable mesh that contains antibacterial agents (medicines that fight infections caused by bacteria) and is wrapped around tissue expanders before being implanted. After approximately 9 weeks, the mesh will fully absorb into the body.

Institution
MUSC
Recruitment Contact
Deanna DeHoff
843-792-8522
dehoff@musc.edu



-- OR --